PharmaFocus Today – Page 64 – media

Cluster development of Changchun’s pharmaceutical and health industry

Recently, the 2024 Changchun International Medical and Health Industry Expo was held in Changchun, Jilin Province. This expo attracted 648 companies to participate, with a total investment of 18.604 billion yuan in signed projects, indicating that Changchun’s pharmaceutical and health industry is gathering strong momentum. Statistics show that in the first 10 months of this year, the scale of the biopharmaceutical and life health industries in Changchun reached 92.5 billion yuan, a year-on-year increase of 10.2%. Jilin Province has abundant medicinal resources, and Changchun is located in the central part of the province, with the advantage of deep processing and utilization of high-quality authentic medicinal materials within the province. At the same time, Changchun is one of the first three biomedicine industry bases recognized by the state, gathering many scientific research institutions such as Chunguang Machinery Institute, President of Chinese Science, Changchun Yinghua Institute, 49 colleges and universities such as ...
- Source: drugdu
- 241
- December 26, 2024
Billions of yuan! Cardiovascular innovative equipment company completes Series C financing

Recently, according to the official WeChat account of Wuhan Weike Medical Technology Co., Ltd. (hereinafter referred to as Weike Medical), Weike Medical has successfully completed its Series C financing, with a financing amount of hundreds of millions of yuan, fully led by Bohua Capital, a well-known investment institution in Liangxi District, Wuxi City. It is reported that this round of financing will provide strong financial support for Weike Medical in product research and development, market expansion, and international strategic layout. According to the Yaozhi Data Investment Pattern Database, Weike Medical has successfully completed four rounds of financing in the three years from 2019 to 2021, with the highest amount being the B-round financing of hundreds of millions of RMB on December 16, 2021, promoting the research and innovation of multiple minimally invasive intervention products, accelerating the product registration and listing process, and bringing better treatment solutions to the vast number ...
- Source: drugdu
- 255
- December 26, 2024
Lianying 5T MR wins bid again, will domestic ultra-high field magnetic resonance imaging explode?

Recently, United Imaging’s first whole-body clinical ultra-high field magnetic resonance uMR Jupiter 5T was selected for the 5.0T magnetic resonance bidding project at the First Affiliated Hospital of Chongqing Medical University, winning the bid for 48 million yuan (RMB). It is worth mentioning that this is the second time that UMC uMR Jupiter 5.0T magnetic resonance imaging has won the bid after entering multiple hospitals such as Southeast University Affiliated Zhongda Hospital, Nanjing Drum Tower Hospital, Suzhou University Affiliated First Hospital, and Fudan University Affiliated Cancer Hospital in 2024. According to the data, the UMR Jupiter 5T is the world’s first 5.0T whole-body magnetic resonance imaging system for the human body. It adopts the industry’s first 5.0T ultra-high field design, redefining the clinical application scope and scientific research prospects of ultra-high field magnetic resonance imaging. At present, the United Imaging uMR Jupiter 5.0T magnetic resonance imaging has obtained NMPA, FDA, ...
- Source: drugdu
- 223
- December 26, 2024
Oncology drug competition has reached a new height

How to become the overlord in the field of oncology? In the past few years, Johnson & Johnson has taught the market a lesson in the field of myeloma. From monoclonal antibodies to CAR-T and then to bispecific antibodies, the number of treatment lines has been extended from the first line to the last line: through the progressive and broad and precise layout, Johnson & Johnson has sought a higher moat for itself and also given latecomers a smaller breakthrough gap. The growth of the overlord of multiple myeloma is in progress. At present, Johnson & Johnson’s layered handover is taking shape, and the revenue of related products in 2023 has exceeded the 10 billion US dollar mark. But such a story is destined not to belong only to Johnson & Johnson. Any powerful pharmaceutical company has its own unique core capabilities, corresponding to a smooth product portfolio echelon management ...
- Source: drugdu
- 111
- December 26, 2024
Planning a Share Swap to Absorb and Merge with Shanghai Raas

On December 22, Haier Biologics (688139) announced that the company is planning to absorb and merge with Shanghai Raas (002252) through a share swap, issuing A-shares to all shareholders of Shanghai Raas and raising matching funds through the issuance of A-shares. The company’s stock is set to be suspended from trading starting December 23 (Monday), with an expected suspension period not exceeding 10 trading days. Haier Biologics stated that during the suspension, the company will actively advance various tasks and, depending on the progress of the matter, will strictly comply with the relevant laws and regulations regarding information disclosure obligations. Once relevant matters are confirmed, the company will promptly release related announcements and apply for the resumption of trading of its stocks. Investors are encouraged to pay attention to subsequent announcements and be cautious about investment risks. On July 29, Shanghai Raas had previously announced a change in the company’s ...
- Source: drugdu
- 336
- December 26, 2024
BaiKe Biological’s Phase II Clinical Trial for Herpes Simplex Virus Type 2 mRNA Vaccine Approved

Shanghai Securities News reported on December 20 that BaiKe Biological announced in the evening that it recently received the “Clinical Trial Approval Notification” issued by the National Medical Products Administration, granting permission to conduct clinical trials for the prevention of genital herpes caused by Herpes Simplex Virus Type 2 (HSV-2) infection. The HSV-2 vaccine approved for clinical trials by the company was jointly submitted with Zhuhai Lifanda Biotechnology Co., Ltd. This vaccine is a multi-component vaccine capable of inducing both humoral immune responses and cellular immune responses, utilizing mRNA technology to further enhance the cellular immune response. Compared to traditional technology routes, it increases the likelihood of successful vaccine development. As of now, there are no related vaccine products successfully developed and marketed globally. BaiKe Biological stated that if this vaccine successfully completes its clinical trials and receives market approval, it will further enrich the company’s product pipeline, help optimize ...
- Source: drugdu
- 213
- December 26, 2024
CanSinoBio Launches Phase II/III Clinical Trials for Adsorbed Acellular DTaP Combined Vaccine

CanSinoBio Launches Phase II/III Clinical Trials for Adsorbed Acellular DTaP Combined Vaccine Finance China News, December 20 – CanSino (688185/06185) released a voluntary disclosure announcing the official launch of Phase II/III clinical trials for its adsorbed acellular DTaP (Diphtheria, Tetanus, and Pertussis) combined vaccine (for individuals aged 6 and older), having completed enrollment of the first subject in Phase II. This vaccine aims to provide booster immunization for adolescents and adults, filling a gap in the domestic market. Currently, the vaccine has completed Phase I clinical trials, with results indicating that its immunogenicity meets expectations and that it is safe. The ongoing Phase II/III clinical trials will further assess the vaccine’s immunogenicity and safety. The company will strictly advance the clinical trials in accordance with national drug registration regulations, despite the complexity and uncertainty inherent in the vaccine development process. In the first three quarters of 2024, CanSino achieved revenue ...
- Source: drugdu
- 263
- December 26, 2024
Chuangxiang Biotechnology and Ikena Oncology merge to raise $75 million in funding

On December 23rd, Ikena Oncology and Inmage Biopharmaceuticals announced that they have signed a final merger agreement. The merged company will focus on developing IMG-007, a monoclonal antibody against OX40 for the treatment of atopic dermatitis. The merged company plans to operate under the name “ImageneBio” and trade on NASDAQ under the stock code “IMA”. This transaction is expected to generate approximately $175 million in funding to support the further development of IMG-007, including $75 million from oversubscribed private equity, which will be completed immediately after the merger This financing includes new investors such as Deep Track Capital, Foresite Capital, RTW Investments, as well as existing Ikena investors such as BVF Partners L.P., Blue Own Healthcare Opportunities, Omega Funds, and OrbiMed. Expected transaction to be completed by mid-2025 picture OX40 is a cost stimulating receptor that primarily exists on activated T cells. In placebo-controlled studies of atopic dermatitis, anti-OX40 mAb ...
- Source: drugdu
- 264
- December 25, 2024
Two biosimilars of pembrolizumab have been approved for marketing, and the second indication of Cononospikinumab has been approved

NO.1 Two biosimilars of pertuzumab approved for market launch On December 23rd, the official website of the State Administration for Market Regulation showed that two types of pertuzumab injections were approved for market, one from Qilu Pharmaceutical and the other from Zhengda Tianqing. Patuximab was originally developed by Roche and was first approved for market by the FDA in 2012. It was first approved for market in China in 2018. Currently, multiple indications have been approved worldwide. Comment: Since its approval, the pertuzumab market has performed exceptionally well, with global sales of $4.2 billion in 2023. As a biosimilar drug, it is expected to occupy a certain market share in the original drug market. But currently, there are 7 domestic companies developing drugs similar to pertuzumab, and competition may intensify in the future. NO.2 Kangnuosipuqibai monoclonal antibody second indication approved On December 23rd, Konya announced that its independently developed ...
- Source: drugdu
- 396
- December 25, 2024
ABB’s maintenance plan based on equipment status helps Jiheng Pharmaceutical

Hebei Jiheng Pharmaceutical Co., Ltd. (hereinafter referred to as “Jiheng Pharmaceutical”) has signed a Motion OneCare worry free service agreement with ABB. Through ABB’s remote status monitoring and fault recovery services, the efficiency and quality of wastewater treatment have been improved, and the normal operation time of sewage pumps has been extended, thereby helping the entire pharmaceutical plant to operate smoothly at a larger capacity. Jiheng Pharmaceutical is located in Hengshui City, Hebei Province, about 250 kilometers south of Beijing, China. Its main products include painkillers, vitamin supplements, and pharmaceutical intermediates. Previously, Jiheng Pharmaceutical wanted to improve the reliability of mechanical vapor recompression (MVR) in the application of wastewater pumps driven by ten motors to enhance the stability of the production line. The MVR process can recover and reuse the energy lost during the evaporation process, thereby improving efficiency and saving energy. However, in recent years, unplanned shutdowns have occurred ...
- Source: drugdu
- 116
- December 25, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.